Nexavar fails second Phase III trial in newly diagnosed advanced lung cancer
This article was originally published in Scrip
Executive Summary
Bayer/Onyx's liver and kidney cancer drug Nexavar (sorafenib) has failed to improve overall survival in combination with chemotherapy in its second Phase III trial, NExUS, in newly diagnosed, advanced non-small cell lung cancer (NSCLC).